116 related articles for article (PubMed ID: 36918223)
1. Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda
Immisch L; Papafotiou G; Popp O; Mertins P; Blankenstein T; Willimsky G
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918223
[No Abstract] [Full Text] [Related]
2. Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch
Chheda ZS; Mueller S; Hegde B; Yamamichi A; Butterfield LH; Okada H
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36944450
[No Abstract] [Full Text] [Related]
3. H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2
Immisch L; Papafotiou G; Popp O; Mertins P; Blankenstein T; Willimsky G
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36302563
[TBL] [Abstract][Full Text] [Related]
4. Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.
Chheda ZS; Kohanbash G; Okada K; Jahan N; Sidney J; Pecoraro M; Yang X; Carrera DA; Downey KM; Shrivastav S; Liu S; Lin Y; Lagisetti C; Chuntova P; Watchmaker PB; Mueller S; Pollack IF; Rajalingam R; Carcaboso AM; Mann M; Sette A; Garcia KC; Hou Y; Okada H
J Exp Med; 2018 Jan; 215(1):141-157. PubMed ID: 29203539
[TBL] [Abstract][Full Text] [Related]
5. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.
Mueller S; Taitt JM; Villanueva-Meyer JE; Bonner ER; Nejo T; Lulla RR; Goldman S; Banerjee A; Chi SN; Whipple NS; Crawford JR; Gauvain K; Nazemi KJ; Watchmaker PB; Almeida ND; Okada K; Salazar AM; Gilbert RD; Nazarian J; Molinaro AM; Butterfield LH; Prados MD; Okada H
J Clin Invest; 2020 Dec; 130(12):6325-6337. PubMed ID: 32817593
[TBL] [Abstract][Full Text] [Related]
6. Histone H3.3K27M Mobilizes Multiple Cancer/Testis (CT) Antigens in Pediatric Glioma.
Deng H; Zeng J; Zhang T; Gong L; Zhang H; Cheung E; Jones C; Li G
Mol Cancer Res; 2018 Apr; 16(4):623-633. PubMed ID: 29453317
[TBL] [Abstract][Full Text] [Related]
7. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.
Huang TY; Piunti A; Lulla RR; Qi J; Horbinski CM; Tomita T; James CD; Shilatifard A; Saratsis AM
Acta Neuropathol Commun; 2017 Apr; 5(1):28. PubMed ID: 28416018
[TBL] [Abstract][Full Text] [Related]
8. Endogenous H3.3K27M derived peptide restricted to HLA-A∗02:01 is insufficient for immune-targeting in diffuse midline glioma.
Wang SS; Pandey K; Watson KA; Abbott RC; Mifsud NA; Gracey FM; Ramarathinam SH; Cross RS; Purcell AW; Jenkins MR
Mol Ther Oncolytics; 2023 Sep; 30():167-180. PubMed ID: 37674626
[TBL] [Abstract][Full Text] [Related]
9. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression.
Chan KM; Fang D; Gan H; Hashizume R; Yu C; Schroeder M; Gupta N; Mueller S; James CD; Jenkins R; Sarkaria J; Zhang Z
Genes Dev; 2013 May; 27(9):985-90. PubMed ID: 23603901
[TBL] [Abstract][Full Text] [Related]
10. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.
Schreck KC; Ranjan S; Skorupan N; Bettegowda C; Eberhart CG; Ames HM; Holdhoff M
J Neurooncol; 2019 May; 143(1):87-93. PubMed ID: 30864101
[TBL] [Abstract][Full Text] [Related]
11. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
[TBL] [Abstract][Full Text] [Related]
12. Histone H3.3K27M Represses
Cordero FJ; Huang Z; Grenier C; He X; Hu G; McLendon RE; Murphy SK; Hashizume R; Becher OJ
Mol Cancer Res; 2017 Sep; 15(9):1243-1254. PubMed ID: 28522693
[TBL] [Abstract][Full Text] [Related]
13. H3.3K27M mutant proteins reprogram epigenome by sequestering the PRC2 complex to poised enhancers.
Fang D; Gan H; Cheng L; Lee JH; Zhou H; Sarkaria JN; Daniels DJ; Zhang Z
Elife; 2018 Jun; 7():. PubMed ID: 29932419
[TBL] [Abstract][Full Text] [Related]
14. An adult case of diffuse midline glioma with H3 K27M mutation.
Tu JH; Piao YS; Lu DH; Wang LM; Liu L; Bai DY; Han HW; Lin YK; Zhong S
Neuropathology; 2020 Dec; 40(6):627-631. PubMed ID: 32954563
[TBL] [Abstract][Full Text] [Related]
15. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
[TBL] [Abstract][Full Text] [Related]
16. Diffuse midline glioma with H3 K27M-mutation in an 83-year-old woman.
Low JT; Wang SH; B Peters K
CNS Oncol; 2021 Jun; 10(2):CNS71. PubMed ID: 33908265
[TBL] [Abstract][Full Text] [Related]
17. PRC2-independent actions of H3.3K27M in embryonic stem cell differentiation.
Cohen LRZ; Kaffe B; Deri E; Leibson C; Nissim-Rafinia M; Maman M; Harpaz N; Ron G; Shema E; Meshorer E
Nucleic Acids Res; 2023 Feb; 51(4):1662-1673. PubMed ID: 36156096
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic activation of a RAS/MYC axis in H3.3K27M-driven cancer.
Pajovic S; Siddaway R; Bridge T; Sheth J; Rakopoulos P; Kim B; Ryall S; Agnihotri S; Phillips L; Yu M; Li C; Milos S; Patel P; Srikanthan D; Huang A; Hawkins C
Nat Commun; 2020 Dec; 11(1):6216. PubMed ID: 33277484
[TBL] [Abstract][Full Text] [Related]
19. H3F3A mutant allele specific imbalance in an aggressive subtype of diffuse midline glioma, H3 K27M-mutant.
Maeda S; Ohka F; Okuno Y; Aoki K; Motomura K; Takeuchi K; Kusakari H; Yanagisawa N; Sato S; Yamaguchi J; Tanahashi K; Hirano M; Kato A; Shimizu H; Kitano Y; Yamazaki S; Yamashita S; Takeshima H; Shinjo K; Kondo Y; Wakabayashi T; Natsume A
Acta Neuropathol Commun; 2020 Feb; 8(1):8. PubMed ID: 32019606
[TBL] [Abstract][Full Text] [Related]
20. Differentiation between spinal cord diffuse midline glioma with histone H3 K27M mutation and wild type: comparative magnetic resonance imaging.
Jung JS; Choi YS; Ahn SS; Yi S; Kim SH; Lee SK
Neuroradiology; 2019 Mar; 61(3):313-322. PubMed ID: 30662997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
